OBSOLETE: Primary intraocular lymphoma Advocacy Hub | UniteRare

At a Glance

Live from database

💊

1FDA treatments

💰

1Open funds

Regulatory Watchboard

No FDA or trial events recorded yet for OBSOLETE: Primary intraocular lymphoma.

Financial Assistance

1 program

FINANCIAL LANDSCAPE SUMMARY

Total programs

Open now

Patient Assistance Programs1

Zevalin

Acrotech Biopharma LLC

OpenContact for detailsApply ↗

View all support programs on disease page →

Approved Treatments

1 FDA-approved

Zevalin

(ibritumomab tiuxetan)Orphan drugstandard

Acrotech Biopharma LLC

12.1 Mechanism of Action Ibritumomab tiuxetan binds specifically to the CD20 antigen (human B-lymphocyte-restricted differentiation antigen, Bp35). Th...

FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for OBSOLETE: Primary intraocular lymphoma.
Search all trials →

Search clinical trials for OBSOLETE: Primary intraocular lymphoma →

Recent News & Research

No recent news articles indexed yet for OBSOLETE: Primary intraocular lymphoma.
Search PubMed for OBSOLETE: Primary intraocular lymphoma →

Browse all OBSOLETE: Primary intraocular lymphoma news →

Specialist Network

No specialists currently listed for OBSOLETE: Primary intraocular lymphoma.

View all OBSOLETE: Primary intraocular lymphoma specialists →

Quick Actions

📄

View Disease Page

Full profile, treatments, community

🔬

Search Clinical Trials

Find recruiting studies now

🩺

Find Specialists

Ranked by expertise & trials

💰

Financial Assistance

Copay cards, PAPs, grants

📰